Human immunodeficiency virus, hepatitis C virus and hepatitis B virus incidence in blood donors from 2000 to 2020 in France: Trends and lessons from haemovigilance surveillance.
HIV, HCV, HBV incidence
blood donors
haemovigilance
Journal
Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
03
08
2023
received:
11
07
2023
accepted:
06
08
2023
pubmed:
11
9
2023
medline:
11
9
2023
entrez:
11
9
2023
Statut:
ppublish
Résumé
Data from 21 years (2000-2020) of haemovigilance were used to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) incidence rates in repeat blood donors and the occurrence of transfusion-transmitted (TT) viral infections. Blood donors who converted for HIV, HCV or HBV markers within serial three-year analysis periods were included. Epidemiological and virological data were retrieved from the national epidemiological donor database and were supplemented with information on blood components and the infection status of recipients of the previous negative donation (D.N-1) of donors who seroconverted. Incidence rates declined from 1.27 to 0.35/100,000 person-years for HIV, from 0.59 to 0.19 for HCV and from 1.66 to 0.18 for HBV. Risk factors and lookback for 232 HIV, 90 HCV and 74 HBV seroconversions were investigated. The main risk factor identified at post-donation interview was having sex with men (47.8% of males) for HIV and a sexual risk for HCV (30.6%) and HBV (37.1%). The viral loads and sequences were retrospectively tested in 191 HIV, 74 HCV and 62 HBV D.N-1 archived samples. Six (five HBV and one HIV-1) were positive all low viral loads. Two recipients were infected by red blood cells from two HBV seroconverting donors before the introduction of HBV-nucleic acid testing. HIV, HCV and HBV incidence rates in blood donors declined over the two past decades in France. There is a very small risk of a blood component that tests negative entering the blood supply resulting in TT infections, especially after introduction of molecular assays in donor screening.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Data from 21 years (2000-2020) of haemovigilance were used to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) incidence rates in repeat blood donors and the occurrence of transfusion-transmitted (TT) viral infections.
MATERIALS AND METHODS
METHODS
Blood donors who converted for HIV, HCV or HBV markers within serial three-year analysis periods were included. Epidemiological and virological data were retrieved from the national epidemiological donor database and were supplemented with information on blood components and the infection status of recipients of the previous negative donation (D.N-1) of donors who seroconverted.
RESULTS
RESULTS
Incidence rates declined from 1.27 to 0.35/100,000 person-years for HIV, from 0.59 to 0.19 for HCV and from 1.66 to 0.18 for HBV. Risk factors and lookback for 232 HIV, 90 HCV and 74 HBV seroconversions were investigated. The main risk factor identified at post-donation interview was having sex with men (47.8% of males) for HIV and a sexual risk for HCV (30.6%) and HBV (37.1%). The viral loads and sequences were retrospectively tested in 191 HIV, 74 HCV and 62 HBV D.N-1 archived samples. Six (five HBV and one HIV-1) were positive all low viral loads. Two recipients were infected by red blood cells from two HBV seroconverting donors before the introduction of HBV-nucleic acid testing.
CONCLUSION
CONCLUSIONS
HIV, HCV and HBV incidence rates in blood donors declined over the two past decades in France. There is a very small risk of a blood component that tests negative entering the blood supply resulting in TT infections, especially after introduction of molecular assays in donor screening.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
843-853Informations de copyright
© 2023 International Society of Blood Transfusion.
Références
Vermeulen M, Chowdhury D, Swanevelder R, Grebe E, Brambilla D, Jentsch U, et al. HIV incidence in South African blood donors from 2012 to 2016: a comparison of estimation methods. Vox Sang. 2021;116:71-80.
Glynn SA, Kleinman SH, Wright DJ, Busch MP, NHLBI Retrovirus Epidemiology Donor Study. International application of the incidence rate/window period model. Transfusion. 2002;42:966-972.
Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The retrovirus epidemiology donor study. N Engl J Med. 1996;334:1685-1690.
Cappy P, Boizeau L, Candotti D, Le Cam S, Martinaud C, Pillonel J, et al. Insights on 21 years of HBV surveillance in blood donors in France. Viruses. 2022;14:2507.
Donneurs de sang en France: chiffres clés 2019-2021. Available from: https://www.santepubliquefrance.fr/les-actualites/2022/donneurs-de-sang-en-france-chiffres-cles-2019-2021
Assal A, Coste J, Barlet V, Laperche S, Cornillot C, Smilovici W, et al. Application of molecular biology to blood transfusion safety: the nucleic acid testing. Transfus Clin Biol. 2003;10:217-226.
Servant-Delmas A, Chuteau C, Lefort C, Piquet Y, Chevaleyre S, Betbeze V, et al. Two cases of transfusion-transmitted hepatitis B virus (HBV) infection in a low-endemic country before implementation of HBV nucleic acid testing. Transfusion. 2013;53:291-296.
Candotti D, Temple J, Sarkodie F, Allain JP. Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa. J Virol. 2003;77:7914-7923.
Pham DA, Leuangwutiwong P, Jittmittraphap A, Luplertlop N, Bach HK, Akkarathamrongsin S, et al. High prevalence of hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol. 2009;27:153-160.
Morice Y, Roulot D, Grando V, Stirnemann J, Gault E, Jeantils V, et al. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol. 2001;82:1001-1012.
Besse B, Coste-Burel M, Bourgeois N, Feray C, Imbert-Marcille BM, Andre-Garnier E. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method. J Virol Methods. 2012;185:94-100.
Brambilla DJ, Busch MP, Dodd RY, Glynn SA, Kleinman SH, National Heart L, et al. A comparison of methods for estimating the incidence of human immunodeficiency virus infection in repeat blood donors. Transfusion. 2017;57:823-831.
Cappy P, Barlet V, Lucas Q, Tinard X, Pillonel J, Gross S, et al. Transfusion of HIV-infected blood products despite highly sensitive nucleic acid testing. Transfusion. 2019;59:2046-2053.
Marty L, Cazein F, Panjo H, Pillonel J, Costagliola D, Supervie V, et al. Revealing geographical and population heterogeneity in HIV incidence, undiagnosed HIV prevalence and time to diagnosis to improve prevention and care: estimates for France. J Int AIDS Soc. 2018;21:e25100.
Laporal S, Leon L, Pioche C, Vaux S, Pillonel J, Lot F, et al. Estimation of the number of acyte hepatitis B diagnoses and exhauxtivuty of mandatory notification in France in 2016, LABOHEP 2016 survey. Bull Epidemiol Hebd. 2019;24-25:469-501.
Germain M, Gregoire Y, Custer BS, Goldman M, Bravo M, Kamel H, et al. An international comparison of HIV prevalence and incidence in blood donors and general population: a BEST collaborative study. Vox Sang. 2021;116:1084-1093.
Pillonel J, Pelat C, Tiberghien P, Sauvage C, Danic B, Martinaud C, et al. The evolving blood donor deferral policy for men who have sex with men: impact on the risk of HIV transmission by transfusion in France. Transfusion. 2020;60:525-534.
Sauvage C, Spinardi R, Pelat C, Pouget T, Danic B, Woimant G, et al. Noncompliance with blood donor selection criteria-Complidon 2017, France. Transfusion. 2020;60:73-83.
Newsum AM, Matser A, Schinkel J, van der Valk M, Brinkman K, van Eeden A, et al. Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: a longitudinal analysis. Clin Infect Dis. 2021;73:460-467.
Popping S, Cuypers L, Claassen MAA, van den Berk GE, De Weggheleire A, Arends JE, et al. Persistent transmission of HCV among men who have sex with men despite widespread screening and treatment with direct-acting antivirals. Viruses. 2022;14:1953.
Leon L, Kasereka S, Barin F, Larsen C, Weill-Barillet L, Pascal X, et al. Age- and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, 2004-2011: model-based estimation from two national cross-sectional serosurveys. Epidemiol Infect. 2017;145:895-907.
Lucidarme D, Duburque C, Bulois P, Filoche B. Evolution of HCV incidence in drug users in France. Epidemiol Infect. 2011;139:1287-1295.
Wilkinson AL, van Santen DK, Traeger MW, Sacks-Davis R, Asselin J, Scott N, et al. Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020. Int J Drug Policy. 2022;103:103655.
Roberts H, Jiles R, Harris AM, Gupta N, Teshale E. Incidence and prevalence of sexually transmitted hepatitis B, United States, 2013-2018. Sex Transm Dis. 2021;48:305-309.
Llaneras J, Riveiro-Barciela M, Rando-Segura A, Marcos-Fosch C, Roade L, Velazquez F, et al. Etiologies and features of acute viral hepatitis in Spain. Clin Gastroenterol Hepatol. 2021;19:1030-1037.
van Houdt R, Bruisten SM, Koedijk FD, Dukers NH, Op de Coul EL, Mostert MC, et al. Molecular epidemiology of acute hepatitis B in the Netherlands in 2004: nationwide survey. J Med Virol. 2007;79:895-901.
Dodd RY, Crowder LA, Haynes JM, Notari EP, Stramer SL, Steele WR. Screening blood donors for HIV, HCV, and HBV at the American Red Cross: 10-year trends in prevalence, incidence, and residual risk, 2007 to 2016. Transfus Med Rev. 2020;34:81-93.
Steele WR, Dodd RY, Notari EP, Haynes J, Anderson SA, Williams AE, et al. HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men. Transfusion. 2021;61:839-850.
Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019;133:1854-1864.
Reynolds C, Davison KL, Brailsford SR. Safe supplies: few infections in UK blood and tissue donors. Transfus Med. 2019;29:239-246.
Gallian P, Pouchol E, Djoudi R, Lhomme S, Mouna L, Gross S, et al. Transfusion-transmitted hepatitis E virus infection in France. Transfus Med Rev. 2019;33:146-153.
Candotti D, Assennato SM, Laperche S, Allain JP, Levicnik-Stezinar S. Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose. Gut. 2019;68:313-321.
Cappy P, Legrain-Jbilou S, Chabli L, N'Debi M, Gallian P, Brisbarre N, et al. SARS-CoV-2 and post-donation information: a one-year experience of the French haemovigilance network. Blood Transfus. 2022;20:362-373.
Gallian P, Cabie A, Richard P, Paturel L, Charrel RN, Pastorino B, et al. Zika virus in asymptomatic blood donors in Martinique. Blood. 2017;129:263-266.
Bone A, Guthmann JP, Assal A, Rousset D, Degeorges A, Morel P, et al. Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, France. PLoS One. 2012;7:e33056.